Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: Prevalence and metabolic consequences

Clinical Infectious Diseases

Volumn 51, Issue 5, 2010, Pages 591-599

  Hammond, Emma ^a   McKinnon, Elizabeth ^a   Nolan, David ^a  

^a MURDOCH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMIVUDINE; MITOCHONDRIAL DNA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INFLAMMATION; INSULIN RESISTANCE; LIPOATROPHY; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; METABOLISM; PRIORITY JOURNAL;

EID: 77955828964     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/655765     Document Type: Article

References (39)

1. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
2. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004; 350:1023-1035.
3. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
4. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidine. J Virol 1998; 72:5093-5098.
5. Nikolenko GN, Palmer S, Maldarelli F, Mellors JW, Coffin JM, Pathak VK. Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision. Proc Natl Acad Sci U S A 2005; 102:2093-2098.
6. Nikolenko GN, Delviks-Frankenberry KA, Palmer S, et al. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'- azido-3'deoxythymidine resistance. Proc Natl Acad Sci U S A 2007; 104:317-322.
7. Delviks-Frankenberry KA, Nikolenko GN, Barr R, Pathak VK. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance. J Virol 2007; 81:6837-6845.
8. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine. J Virol 2007; 81: 7852-7859.
9. Yap SH, Sheen CW, Fahey J, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4:e335.
10. Ehteshami M, Beilhartz GL, Scarth BJ, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms. J Biol Chem 2008; 283:22222-22232.
11. Ehteshami M, Gotte M. Effects of mutations in the connection and RNase H domains of HIV-1 reverse transcriptase on drug susceptibility. AIDS Rev 2008; 10:224-235.
12. Cane PA, Green H, Fearnhill E, Dunn D. Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS 2007; 21:447-455.
13. Hachiya A, Kodama EN, Sarafianos SG, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008; 82:3261-3270.
14. Waters JM, O'Neal W, White KL, et al. Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients. Antivir Ther 2009; 14:231-239.
15. Price H, Asboe D, Pozniak A, et al. Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data. Antivir Ther 2010; 15:203-211.
16. von Wyl V, Ehteshami M, Symons J, et al. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis 2010; 201:1054-1062.
17. Hachiya A, Shimane K, Sarafianos SG, et al. Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV- 1 reverse transcriptase from a cohort of antiretroviral treatment-naive patients. Antiviral Res 2009; 82:115-121.
18. Brehm J, Sheen CW, Hughes M, et al. Virologic failure of regimens containing two NRTIs plus efavirenz is not associated with the selection of mutations in the connection or RNase H domains of reverse transcriptase. Antivir Ther 2009; 14:A34.
19. Paredes RBW, Cozzi-Lepri A, Pou C, et al; EuroSIDA Study Group. Mutation A376S in the RT connection domain is associated with an increased risk of virological failure to nevirapine-based therapy in NNRTI-naïve HIV-infected subjects in the EuroSIDA study. In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. 2009. Abstract 646.
20. Dau B, Ayers D, Singer J, et al. Connection domain mutations in treatment-experienced patients in the OPTIMA trial. J Acquir Immune Defic Syndr 2010; 54:160-166.
21. Demeter LM, Hughes MD, Coombs RW, et al. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine: AIDS Clinical Trials Group Protocol 320. Ann Intern Med 2001; 135:954-964.
22. Hammer SM, Squires KE, Hughes MD, et al; AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-733.
23. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study-Swiss HIV Cohort Study. Lancet 1999; 353:863-868.
24. von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-1790.
25. Nijhuis M, Schuurman R, de Jong D, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997; 176:398-405.
26. Dunn D, von Wyl V, Price H, Asboe D. The impact of the 0-0 cell on measures of amino acid covariation. AIDS 2010; 24:159-160.
27. Svicher V, Sing T, Santoro MM, et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006; 80:7186-7198.
28. Deforche K, Silander T, Camacho R, et al. Analysis of HIV-1 pol sequences using Bayesian networks: implications for drug resistance. Bioinformatics 2006; 22:2975-2979.
29. Hammer SM, Eron JJ Jr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society- USA panel. JAMA 2008; 300:555-570.
30. Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete- time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 1999; 18:2655-2679.
31. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, Shafer RW. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Research 2003; 31:298-303.
32. Myllymaki P, Silander T, Tirri H, Uronen P. B-course: a Web-based tool for Bayesian and causal data analysis. Int J Artif Intell Tools 2002; 11:369-387.
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate-a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995; 57:289-300.
34. Rhee SY, Liu TF, Holmes SP, Shafer RW. HIV-1 subtype B protease and reverse transcriptase amino acid covariation. PLoS Comput Biol 2007; 3:e87.
35. Marcelin AG, Delaugerre C, Wirden M, et al. Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure. J Med Virol 2004; 72:162-165.
36. Yahi N, Tamalet C, Tourres C, et al. Mutation patterns of the reverse transcriptase and protease genes in human immunodeficiency virus type 1-infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol 1999; 37:4099-4106.
37. Gotte M. Should we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testing. PLoS Med 2007; 4:e346.
38. Roquebert B, Marcelin AG. The involvement of HIV-1 RNAse H in resistance to nucleoside analogues. J Antimicrob Chemother 2008; 61: 973-975.
39. McCormick ABA, Katundu P, Lyagoba F, et al; DART Virology Group. Prevalence and in vitro characteristics of reverse transcriptase (RT) N348I mutation in non b subtypes, in the absence of viral load monitoring, in the DART study (NORA substudy). In: Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections. 2009. Abstract 643.